CS
TARS icon

Credit Suisse’s Tarsus Pharmaceuticals TARS Stock Holding History

Credit Suisse’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$998K Buy
27,455
+440
+2% +$12.9K ﹤0.01% 2271
2023
Q4 		$547K Buy
27,015
+938
+4% +$15.7K ﹤0.01% 2687
2023
Q3 		$463K Buy
26,077
+3,635
+16% +$64.3K ﹤0.01% 2721
2023
Q2 		$406K Buy
22,442
+6,889
+44% +$110K ﹤0.01% 2886
2023
Q1 		$196K Buy
15,553
+2,118
+16% +$31K ﹤0.01% 3120
2022
Q4 		$197K Buy
13,435
+13,332
+12,944% +$221K ﹤0.01% 3186
2022
Q3 		$2K Buy
103
+90
+692% +$1.43K ﹤0.01% 3765
2022
Q2 		$0 Buy
+13
New +$195 ﹤0.01% 4302

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Credit Suisse's TARS Position: Q1 2024 in Review

Credit Suisse increased its Tarsus Pharmaceuticals (TARS) stake by 1.6% in Q1 2024, buying an estimated $12.9K and bringing the position to 27,455 shares worth $998K. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

Credit Suisse first reported a position in TARS in Q2 2022 and has held it in 8 quarters since. 157 funds tracked by Wall St. Rank hold TARS as of Q1 2024.

  • Credit Suisse held 27,455 shares of Tarsus Pharmaceuticals worth $998K as of Q1 2024.
  • Credit Suisse bought 440 Tarsus Pharmaceuticals shares in Q1 2024, an estimated $12.9K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2271 holding.
  • Credit Suisse first reported a position in Tarsus Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
  • 157 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.